Allspring Global Investments Holdings LLC Boosts Stake in Bristol Myers Squibb Company $BMY

Allspring Global Investments Holdings LLC grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,095,654 shares of the biopharmaceutical company’s stock after acquiring an additional 57,224 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.05% of Bristol Myers Squibb worth $67,635,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth approximately $1,947,272,000. AQR Capital Management LLC lifted its holdings in Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after purchasing an additional 7,837,485 shares during the period. Geode Capital Management LLC grew its holdings in Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Finally, Man Group plc grew its holdings in Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BMY. Guggenheim reissued a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Bristol Myers Squibb in a report on Thursday, July 2nd. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Trading Up 0.3%

Shares of BMY stock opened at $60.71 on Friday. The firm’s 50 day moving average price is $57.02 and its two-hundred day moving average price is $57.78. The stock has a market cap of $123.97 billion, a price-to-earnings ratio of 17.05, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.34 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in relapsed/refractory multiple myeloma, a meaningful regulatory step that could strengthen the company’s oncology pipeline and future revenue prospects. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusual options activity showed traders buying a notably higher-than-average number of call options, suggesting some investors are positioning for additional upside in BMY.
• Positive Sentiment: Recent commentary highlighted Bristol Myers Squibb as a strong value stock, reinforcing the view that the shares may still look attractive on valuation grounds. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Brokerage coverage continues to point to a “Hold” consensus, indicating analysts are not broadly turning more bullish or bearish on the stock. Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Brokerages
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate to $6.10 from $6.12, but the change is modest and still near consensus, so it is unlikely to be a major near-term driver by itself.
• Negative Sentiment: The small downward revision to longer-term earnings expectations may indicate some caution around Bristol Myers Squibb’s post-2026 growth trajectory, which could limit enthusiasm if investors focus on future profitability.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.